AbCheck S.R.O.

Fully human library, In vivo-generated diversity of antibody sequences comprising sequential as well as structural diversity, New combinations of VH and VL chains from multiple healthy donors, No bias from amplification of the VH chains by IgM specific priming, Special assembly technology guarantees >70% functional clones.

AbCheck is exploiting the commercial potential of its platform technologies in research collaborations with biotechnology and pharmaceutical partners.

The AbCheck antibody libraries are highly productive and have been validated in preclinical programs. AbCheck’s track record of antibody research, comprising more than 25 successfully completed ‘pannings’ includes difficult targets and targets with high demands on specificity. Development times are well within the industry standards.

AbCheck is positioned as a one-stop-shop partner for antibody research, offering a complete package of discovery services and capabilities. The company’s service portfolio covers all aspects of antibody discovery, from early stage research to lead optimisation. AbCheck antibodies are specifically tuned to the pre-defined specifications of our commercial partners.

The company enjoys a strong IP position and full freedom to operate without royalty obligations to third parties. This favourable position allows AbCheck to offer a unique value proposition: fully validated technology, low cost structures and deal terms with no commercial obligations to third parties.

As many established antibody discovery firms have either been acquired or undergone a change of strategy to focus on propriety drug development while shifting away from research collaborations, AbCheck has stepped in to fill the gap.

AbCheck s.r.o. is located in the technology park of Plzen, Czech Republic.

Fully human library, In vivo-generated diversity of antibody sequences comprising sequential as well as structural diversity, New combinations of VH and VL chains from multiple healthy donors, No bias from amplification of the VH chains by IgM specific priming, Special assembly technology guarantees >70% functional clones.